Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models

Journal of Autoimmunity

Volumn 27, Issue 3, 2006, Pages 182-195

  Rosloniec, Edward F ^a,b   Brandstetter, Tilmann ^c   Leyer, Sigmar ^c   Schwaiger, Franz Werner ^d   Nagy, Zoltan A ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c GPC Biotech AG   (Germany)

^d Aurigon Life Science GmbH   (Germany)

Author keywords

Autoimmunity; MHC class II; Peptidomimetics; Therapy

Indexed keywords

CATHEPSIN; COLLAGEN; HLA DR ANTIGEN; METHOTREXATE; PEPTIDE DERIVATIVE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INHIBITION; DRUG STABILITY; DRUG SYNTHESIS; HYDROPHOBICITY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; TRANSGENIC MOUSE;

ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; BINDING, COMPETITIVE; DISEASE MODELS, ANIMAL; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MOLECULAR MIMICRY; OLIGOPEPTIDES; PEPTIDE HYDROLASES;

EID: 33845968012     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2006.09.005     Document Type: Article

References (49)

1. Nepom B.S. The role of the major histocompatibility complex in autoimmunity. Clin Immunol Immunopathol 67 (1993) S50-S55
2. Schiff B., Mizrachi Y., Orgad S., Yaron M., and Gazit I. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis 41 (1982) 403-404
3. McMichael S.J., Sasazuki T., McDevitt H.O., and Payne R.O. Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum 20 (1977) 1037-1042
4. Wordsworth B.P., Lanchbury J.S., Sakkas L.I., Welsh K.I., Panayi G.S., and Bell J.I. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A 86 (1989) 10049-10053
5. Spielman R.S., and Nathanson N. The genetics of susceptibility to multiple sclerosis. Epidemiol Rev 4 (1982) 45-65
6. Hillert J., Kall T., Vrethem M., Fredrikson S., Ohlson M., and Olerup O. The HLA-Dw2 haplotype segregates closely with multiple sclerosis in multiplex families. J Neuroimmunol 50 (1994) 95-100
7. Gregersen P.K., Silver J., and Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 (1987) 1205-1213
8. Dessen A., Lawrence C.M., Cupo S., Zaller D.M., and Wiley D.C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7 (1997) 473-481
9. Smith K.J., Pyrdol J., Gauthier L., Wiley D.C., and Wucherpfennig K.W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 188 (1998) 1511-1520
10. β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329 (1987) 599-604
11. Wucherpfennig K.W., Yu B., Bhol K., Monos D.S., Argyris E., Karr R.W., et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci U S A 92 (1995) 11935-11939
12. Hammer J., Gallazzi F., Bono E., Karr R.W., Guenot J., Valsasini P., et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med 181 (1995) 1847-1855
13. Nepom B.S., Nepom G.T., Coleman M., and Kwok W.W. Critical contribution of β chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules. Proc Natl Acad Sci U S A 93 (1996) 7202-7206
14. Wucherpfennig K.W., and Strominger J.L. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune disease. J Exp Med 181 (1995) 1597-1601
15. Sinigaglia F., and Nagy Z.A. Structural basis for the HLA-DR association of rheumatoid arthritis. In: Goronczy J.J., and Weyand C.M. (Eds). Rheumatoid arthritis. Curr Dir Autoimmun 3 (2001), Karger, Basel 36-50
16. Hammer J., Takacs B., and Sinigaglia F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 176 (1992) 1007-1013
17. Hammer J., Valsasini P., Tolba K., Bolin D., Higelin J., Takacs B., et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74 (1993) 197-203
18. Hammer J., Belunis C., Bolin D., Papadopoulos J., Walsky R., Higelin J., et al. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc Natl Acad Sci U S A 91 (1994) 4456-4460
19. Hammer J., Bono E., Gallazzi F., Belunis C., Nagy Z., and Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 180 (1994) 2353-2358
20. Adorini L., and Nagy Z. Inhibition of T cell activation by MHC blockade. Int Rev Immunol 6 (1990) 23-35
21. Adorini L., Muller S., Cardinaux F., Lehmann P.V., Falcioni F., and Nagy Z.A. In vivo competition between self peptides and foreign antigens in T-cell activation. Nature 334 (1988) 623-625
22. Guagliardi L.E., Koppelman B., Blum J.S., Marks M.S., Cresswell P., and Brodsky F.M. Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment. Nature 343 (1990) 133-139
23. Harding C.V., and Geuze H.J. Immunogenic peptides bind to class II MHC molecules in an early lysosomal compartment. J Immunol 151 (1993) 3988-3998
24. Falcioni F., Ito K., Vidovic D., Belunis C., Campbell R., Berthel S.J., et al. Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Nat Biotechnol 17 (1999) 562-567
25. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364 (1993) 33-39
26. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368 (1994) 215-221
27. Bolin D.R., Swain A.L., Sarabu R., Berthel S.J., Gillespie P., Huby N.J.S., et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J Med Chem 43 (2000) 2135-2148
28. Rosloniec E.F., Brand D.D., Myers L.K., Whittington K.B., Gumanovskaya M., Zaller D.M., et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 185 (1997) 1113-1122
29. Rosloniec E.F., Brand D.D., Myers L.K., Esaki Y., Whittington K.B., Zaller D.M., et al. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol 160 (1998) 2573-2578
30. Ito K., Bian H.-J., Molina M., Han J., Magram J., Saar E., et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 183 (1996) 2635-2644
31. Sarabu S., Bolin D.R., Campbell R., Cooper J.P., Cox D., Gaizband D., et al. Oxazole- and imidazole-based Ser-Leu dipeptide mimetics in potent inhibitors of antigen presentation by MHC Class II DR molecules. Drug Des Discov 18 (2002) 3-7
32. Chung J.Y.L., Wasicak J.T., Arnold W.A., May C.S., Nadzan A.N., and Holladay M.W. Conformationally constrained amino acids. Synthesis and optical resolution of 3-substituted proline derivatives. J Org Chem 55 (1990) 270-275
33. Gorga J.C., Horejsi V., Johnson D.R., Raghupathy R., and Strominger J.L. Purification and characterisation of class II histocompatibility antigens from a homozygous human B cell line. J Biol Chem 262 (1987) 16087-16094
34. Gorga J.C., Knudsen P.J., Foran J.A., Strominger J.L., and Burakoff S.J. Immunochemically purified DR antigens in liposomes stimulate xenogeneic cytotoxic T cells in secondary in vitro cultures. Cell Immunol 103 (1986) 160-173
35. Siklodi B., Vogt A.B., Kropshofer H., Falcioni F., Molina M., Bolin D.R., et al. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells. Human Immunol 59 (1998) 463-471
36. Garrett E.R., and Gardner M.R. Predictions of stability in pharmaceutical preparations. XIX. Stability evaluation and bioanalysis of clofibric acid esters by high-pressure liquid chromatography. J Pharm Sci 71 (1982) 14-25
37. White J., Blackman M., Bill J., Kappler J., Marrack P., Gold D., et al. Two better cell lines for making hybridomas expressing specific T cell receptors. J Immunol 143 (1989) 1822-1825
38. Rosloniec E.F., Kang A.H., Myers L.K., and Cremer M.A. Collagen-induced arthritis. Current protocols in immunology vol. 2 (1997), Wiley & Sons, NY 15.5.1 Unit 15.5
39. Stefferl A., Schubart A., Storch M., Amini A., Mather I., Lassmann H., et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J Immunol 165 (2000) 2859-2865
40. Belpaire F.M., and Bogaert M.G. The fate of xenobiotics in living organisms. In: Wermuth C.G. (Ed). The practice of medicinal chemistry. 2nd ed. (2003), Academic Press, An imprint of Elsevier Science, Amsterdam, Boston, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo 501-515
41. Nagy Z.A., Hubner B., Löhning C., Rauchenberger R., Reiffert S., Thomassen-Wolf E., et al. Fully human, HLA-DR specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 8 (2002) 801-807
42. Vidovic D., Falcioni F., Siklodi B., Belunis C.J., Bolin D.R., Ito K., et al. Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments. Eur J Immunol 25 (1995) 3349-3355
43. Yentur S.P., Akman-Demir G., Eraksoy M., and Saruhan-Direskeneli G. Autoreactivity to myelin antigens related to HLA associations with multiple sclerosis. Mult Scler 8 (2002) 278-283
44. Guerini F.R., Ferrante P., Losciale L., Caputo D., Lombardi M.L., Pirozzi G., et al. Myelin basic protein gene is associated with MS in DR4- and DR5-positive Italians and Russians. Neurology 61 (2003) 520-526
45. Ishioka G.Y., Adorini L., Guery J.-C., Gaeta F.C.A., LaFond R., Alexander J., et al. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for the therapeutic potential of MHC-blocking peptides. J Immunol 152 (1994) 4310-4319
46. Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317 (1987) 408-414
47. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45 (1995) 1268-1276
48. Fridkis-Hareli M., and Strominger J.L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 160 (1998) 4386-4397
49. Fridkis-Hareli M., Neveu J.M., Robinson R.A., Lane W.S., Gauthier K., Wucherpfennig W., et al. Binding motifs of Copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol 162 (1999) 4697-4704